Urine RNA Test Achieves 95 Percent Accuracy in Bladder Cancer Detection
A new diagnostic test analyzes cell-free RNA fragments in urine to identify bladder cancer with 95% accuracy, outperforming standard cytology and DNA-based liquid biopsy methods. Published on October 2, 2026, in Nature Medicine, the study was conducted by researchers at Stanford Medicine and the Veterans Affairs Palo Alto Health Care System, evaluating 683 clinical urine samples from patients and healthy controls.
How the uRARE-seq RNA Analysis Works
Unlike traditional liquid biopsies that primarily search biological fluids for DNA mutations, the new method—named uRARE-seq—focuses on cell-free RNA molecules. As explained by senior study author Maximilian Diehn, measuring tumor DNA simply confirms whether cancer exists, whereas analyzing RNA reveals what the cancer is actively doing. The test adapts RNA sequencing techniques to isolate rare RNA fragments in urine, mapping the biological activity of active genes in the tissue. In evaluations reported by Nature Medicine, the assay correctly identified 95% of localized bladder cancer cases and accurately recognized roughly 90% of non-cancer samples as negative.
Comparing Diagnostic Accuracy with Standard Methods
The urine RNA assay demonstrates distinct advantages over existing non-invasive alternatives. According to sanitainformazione.it, uRARE-seq surpasses standard urine cytology and DNA-based tests by analyzing active gene expression rather than structural mutations. DNA tests often encounter false positives due to normal bladder lining cells accumulating mutations that mimic cancer, a phenomenon known as field effect. By reading the immediate genetic activity, uRARE-seq successfully distinguishes between low-grade and high-grade bladder tumors while avoiding background genomic noise.
Guiding Post-Surgical Immunotherapy and Monitoring
Beyond initial detection, the RNA profile offers critical insights into treatment response and residual disease. Following surgical removal, patients frequently receive intravesical immunotherapy using the Bacillus Calmette-Guérin (BCG) vaccine strain.
Despite high diagnostic percentages, researchers emphasize that the test cannot immediately replace routine procedures. Current European guidelines continue to base non-muscle-invasive bladder cancer monitoring on cystoscopy—a procedure using a thin camera inserted through the urethra—scheduled every three months for high-risk patients. Because the test’s 95% sensitivity still leaves a margin of undetected tumors, and its 90% specificity does not eliminate the need for direct visual inspection, study authors stress that larger, multicenter prospective trials are required before uRARE-seq enters standard clinical practice.
Frequently Asked Questions
What biological material does the uRARE-seq test analyze?
The test analyzes cell-free RNA fragments released by tumor cells into urine samples. These molecular pieces show which genes are actively functioning rather than just tracking structural DNA mutations.
How many samples were evaluated in the Stanford Medicine study?
Researchers evaluated a total of 683 urine samples collected from patients and healthy control subjects, as detailed in the October 2026 publication in Nature Medicine.
Will this urine test replace regular cystoscopy exams?
Not immediately. While the test provides valuable supplementary data on tumor behavior and treatment response, clinical guidelines still rely on direct cystoscopy examination to monitor high-risk patients until prospective trials confirm the test’s safety in delaying invasive procedures.
Worth a look